Q2 2024 EPS Estimates for Danaher Co. Decreased by Leerink Partnrs (NYSE:DHR)

Danaher Co. (NYSE:DHR) – Equities researchers at Leerink Partnrs cut their Q2 2024 earnings per share estimates for Danaher in a research note issued to investors on Tuesday, April 23rd. Leerink Partnrs analyst P. Souda now anticipates that the conglomerate will post earnings per share of $1.56 for the quarter, down from their previous estimate of $1.66. The consensus estimate for Danaher’s current full-year earnings is $7.64 per share. Leerink Partnrs also issued estimates for Danaher’s Q2 2025 earnings at $1.87 EPS, Q3 2025 earnings at $1.94 EPS and Q4 2025 earnings at $2.64 EPS.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, topping the consensus estimate of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.62 billion. During the same quarter last year, the company earned $2.36 earnings per share. The company’s quarterly revenue was down 2.6% on a year-over-year basis.

Other research analysts also recently issued reports about the company. HSBC raised Danaher from a “hold” rating to a “buy” rating and increased their price objective for the company from $250.00 to $280.00 in a research note on Wednesday, April 17th. Bank of America raised their target price on Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a research report on Wednesday. Robert W. Baird raised their price target on Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a research note on Wednesday. Citigroup raised their price target on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, Royal Bank of Canada raised their price target on Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. Six research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $270.00.

Danaher Stock Down 1.8 %

Danaher stock opened at $245.82 on Friday. The stock has a market capitalization of $182.08 billion, a PE ratio of 41.66, a price-to-earnings-growth ratio of 4.19 and a beta of 0.83. Danaher has a 12 month low of $182.09 and a 12 month high of $259.00. The business has a 50 day simple moving average of $248.94 and a 200-day simple moving average of $230.88. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.37.

Danaher Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Investors of record on Thursday, March 28th will be issued a dividend of $0.27 per share. The ex-dividend date is Wednesday, March 27th. This is a boost from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 annualized dividend and a yield of 0.44%. Danaher’s payout ratio is currently 18.31%.

Insider Buying and Selling

In other news, CEO Rainer Blair sold 47,175 shares of the business’s stock in a transaction on Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total value of $11,756,953.50. Following the completion of the transaction, the chief executive officer now directly owns 115,995 shares of the company’s stock, valued at $28,908,273.90. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, Director Teri List sold 3,289 shares of the company’s stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total value of $816,724.48. Following the completion of the transaction, the director now directly owns 19,726 shares in the company, valued at $4,898,360.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Rainer Blair sold 47,175 shares of the business’s stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total value of $11,756,953.50. Following the sale, the chief executive officer now directly owns 115,995 shares of the company’s stock, valued at approximately $28,908,273.90. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 84,132 shares of company stock valued at $21,022,795. 11.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Danaher

Several institutional investors and hedge funds have recently modified their holdings of DHR. Norges Bank acquired a new position in shares of Danaher in the fourth quarter worth about $1,752,382,000. Wellington Management Group LLP lifted its stake in shares of Danaher by 18.6% in the third quarter. Wellington Management Group LLP now owns 24,930,281 shares of the conglomerate’s stock worth $6,185,203,000 after acquiring an additional 3,905,449 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its stake in shares of Danaher by 214.4% in the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 3,073,661 shares of the conglomerate’s stock worth $711,051,000 after acquiring an additional 2,096,038 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Danaher by 10.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock worth $3,876,694,000 after acquiring an additional 1,619,586 shares in the last quarter. Finally, Capital International Investors lifted its stake in shares of Danaher by 9.1% in the fourth quarter. Capital International Investors now owns 15,956,519 shares of the conglomerate’s stock worth $3,691,735,000 after acquiring an additional 1,334,781 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.